Synthis

[Available On-Demand]
Search General Info
Search Education
Search Partnering Companies
Synthis is a NYC-based biotech company developing a first in class, therapeutic platform that restores immune function and tumor clearance in checkpoint resistant cancer patients. While immune checkpoint inhibitors are 1st line treatment for many cancers, <30% of all patients actually respond. Our platform selectively eliminates one of the most immune-suppressive pathways in all solid tumors, known as TGF-b. TGF-b also drives resistance to checkpoint therapies. To address the significant need for novel combination therapies, we are developing targeted TGF-b inhibitors that combine with checkpoint therapies to boost response patient response rates in cancers such as colon, skin and liver.
Company Type:
Company HQ State:
New York
Company HQ Country:
United States
Year Founded:
2015
Main Therapeutic Focus:
Lead Product in Development:
SYN-101
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
CEO
Synthis